Evidence map›Paper›PMID 27171110›Full record

ReviewNutrients2016

The Potential Protective Effects of Polyphenols in Asbestos-Mediated Inflammation and Carcinogenesis of Mesothelium.

Monica Benvenuto, Rosanna Mattera, Gloria Taffera, Maria Gabriella Giganti, Paolo Lido, Laura Masuelli, Andrea Modesti, Roberto Bei

Open access · goldAbstract readReview
In one paragraph

Review in Nutrients, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Frontiers in pharmacology · 2017
    Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Monica BenvenutoDepartment of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", Rome 00133, Italy. monicab4@hotmail.it.
Rosanna MatteraDepartment of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", Rome 00133, Italy. rosannamatter@gmail.com.
Gloria TafferaDepartment of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", Rome 00133, Italy. g.taffera@gmail.com.
Maria Gabriella GigantiDepartment of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", Rome 00133, Italy. giganti@med.uniroma2.it.
Paolo LidoInternal Medicine Residency Program, University of Rome "Tor Vergata", Rome 00133, Italy. paulshore@virgilio.it.
Laura MasuelliDepartment of Experimental Medicine, University of Rome "Sapienza", Rome 00164, Italy. Laura.masuelli@uniroma1.it.
Andrea ModestiDepartment of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", Rome 00133, Italy. modesti@med.uniroma2.it.
Roberto BeiDepartment of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", Rome 00133, Italy. bei@med.uniroma2.it.
University of Rome Tor Vergata · ITSapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant Mesothelioma (MM) is a tumor of the serous membranes linked to exposure to asbestos. A chronic inflammatory response orchestrated by mesothelial cells contributes to the development and progression of MM. The evidence that: (a) multiple signaling pathways are aberrantly activated in MM cells; (b) asbestos mediated-chronic inflammation has a key role in MM carcinogenesis; (c) the deregulation of the immune system might favor the development of MM; and (d) a drug might have a better efficacy when injected into a serous cavity thus bypassing biotransformation and reaching an effective dose has prompted investigations to evaluate the effects of polyphenols for the therapy and prevention of MM. Dietary polyphenols are able to inhibit cancer cell growth by targeting multiple signaling pathways, reducing inflammation, and modulating immune response. The ability of polyphenols to modulate the production of pro-inflammatory molecules by targeting signaling pathways or ROS might represent a key mechanism to prevent and/or to contrast the development of MM. In this review, we will report the current knowledge on the ability of polyphenols to modulate the immune system and production of mediators of inflammation, thus revealing an important tool in preventing and/or counteracting the growth of MM.

Indexed as

AnimalsAsbestosCarcinogenesisHumansInflammationLung NeoplasmsMesotheliomaMesothelioma, MalignantPolyphenolsAsbestosPolyphenolsasbestosimmune systeminflammationmalignant mesotheliomapolyphenolsROS and RNS

Identifiers

PMID27171110
PMCPMC4882688
OpenAlexW2345780899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.